标题:LBO1-01 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study.讲者: Peter Schmid,Centre for Experimental Cancer Medicine,United Kingdom
■ BCT1902/IBCSG 61-20 Neo-N研究:新辅助纳武利尤单抗(N)单药治疗(2周),之后接受N+化疗(12周)vs 同时接受N+化疗治疗TNBC的II期随机研究 标题:LBO1-03 Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N).讲者:Sherene Loi, Peter MacCallum Cancer Centre,Australia;
探HER2+ BC治疗新方案,优化临床治疗策略 ■ APTneo Michelangelo研究:阿替利珠单抗新辅助治疗HER2+早期高危和局部进展期BC的病理完全缓解(pCR)疗效 标题:LBO1-02 Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial.讲者:Luca Gianni, Fondazione Michelangelo, Italy
■ zanidatamab+哌柏西利(palbo)+氟维司群(fulv)治疗HER2+/HR+转移性乳腺癌(mBC)的2a期研究主要结果 标题:LBO1-04 Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant(fulv) in HER2+/HR+ metastatic breast cancer (mBC).讲者:Santiago Escrivá-de-Romani ,Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Spain
注释:Ⅲ期PALOMA-3研究表明,在二线治疗的HER2+/HR+晚期BC患者中palbo+fulv的 PFS 优于氟维司群单药,并显示出具有临床意义的 OS 获益。Zanidatamab 是一种人源化、双特异性单克隆抗体,可以同时结合两个非重叠的HER-2表位,即双互补位结合。目前,Zanidatamab已获美国食品药品监督管理局(FDA)孤儿药认定,用于治疗胆道癌、胃癌和卵巢癌。为进一步满足HER2+BC治疗的临床需求,研究人员对新型抗HER2药物展开了一系列探索,此次SABCS上报道了一项Zanidatamab联合palbo+fulv治疗HER2+/HR+ 局部晚期或转移性BC的多中心、II期研究。
OFS在中高危人群获益再添新证,HR+/HER2- BC或可豁免化疗 ■ ADAPTcycle研究:年龄和卵巢功能抑制(OFS)对HR+/HER2-早期乳腺癌患者术前内分泌治疗(ET)应答的影响 (n=4334) 标题:LBO1-05 Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334).讲者:Oleg Gluz,West German Study Group, , Germany